ABSTRACT: A complex with the C-terminal portion of the proteosomal subunit S6 ATPase is the only available structure of a protein−protein interaction involving the oncoprotein gankyrin. However, difficulties associated with recombinant expression of S6 ATPase alone, or truncations thereof, have limited our understanding of this assembly. We replaced the C-terminal portion of FtsH from Escherichia coli with the structurally homologous Cterminal portion of S6 ATPase and used this grafted protein to characterize the gankyrin−S6 ATPase binding interaction by isothermal titration calorimetry. Gankyrin is reported to bind both cyclin-dependent kinase 4 (CDK4) 8 and MDM2, 9 resulting in increased efficiency of pRb phosphorylation and p53 polyubiquitination and degradation, respectively. However, the structural basis for these interactions has not yet been reported, and neither the targets nor their putative gankyrin binding domains are expressed as soluble recombinant proteins in Escherichia coli. A more promising venue for studying gankyrin−protein interactions is the cocrystal structure with a C-terminal portion of the S6 ATPase from the 26S proteasome, reported by Yokoyama and coworkers ( Figure 1a) . 10 Preliminary characterization of the recognition interface by Yokoyama and co-workers was achieved by a series of pull-down experiments with gankyrinHis 6x and S6 ATPase mutants (concomitantly expressed from a pET-Duet plasmid), in which binding face residues thought to participate in complex stability were mutated to mostly alanine [R342A, R338A/R342A, R338A/R339A/R342A, E356A/ E357A, D359A/D362A, and K397E in S6 ATPase and R41A, K116A, D39A/D71A, R41A/K116A, and E182A in gankyrin (highlighted in Figure 1b) ].
Protein−protein interactions (PPIs) involving gankyrin are of great interest in basic research and as therapeutic targets.
Gankyrin is reported to bind both cyclin-dependent kinase 4 (CDK4) 8 and MDM2, 9 resulting in increased efficiency of pRb phosphorylation and p53 polyubiquitination and degradation, respectively. However, the structural basis for these interactions has not yet been reported, and neither the targets nor their putative gankyrin binding domains are expressed as soluble recombinant proteins in Escherichia coli. A more promising venue for studying gankyrin−protein interactions is the cocrystal structure with a C-terminal portion of the S6 ATPase from the 26S proteasome, reported by Yokoyama and coworkers ( Figure 1a) . 10 Preliminary characterization of the recognition interface by Yokoyama and co-workers was achieved by a series of pull-down experiments with gankyrinHis 6x and S6 ATPase mutants (concomitantly expressed from a pET-Duet plasmid), in which binding face residues thought to participate in complex stability were mutated to mostly alanine [R342A, R338A/R342A, R338A/R339A/R342A, E356A/ E357A, D359A/D362A, and K397E in S6 ATPase and R41A, K116A, D39A/D71A, R41A/K116A, and E182A in gankyrin (highlighted in Figure 1b) ].
Efforts to directly probe the gankyrin−S6 ATPase complex are hampered by the tendency of the latter to form inclusion bodies when expressed in the absence of gankyrin. In our hands, such material could not be refolded, and fusion to proteins commonly used to improve stability and solubility was likewise ineffective. An alternative strategy for the display of folded and functional S6 ATPase is protein grafting. In this approach, a protein scaffold is identified that is stable, is expressed well in E. coli, and contains a domain with excellent structural homology to S6 ATPase. If that protein is stable enough to tolerate replacement of the structurally homologous domain with S6 ATPase, it could serve as a generic platform for the display of a folded and functional variant of this otherwise inaccessible protein.
Our initial efforts to identify such a scaffold relied on the recognition by Yokoyama and co-workers that, while the Cterminal portion of FtsH from E. coli has a low level of sequence homology (∼25%) with S6 ATPase, the two proteins have similar tertiary structures [root-mean-square deviation of ∼1.4 Å over 74 main chain residues (Figure 1c) ]. Expanding on this finding, we set out to determine if a grafted protein, in Figure S1 ). Circular dichroism spectra of the two proteins are virtually identical (Figure 2a ), suggesting no appreciable structural change to the FtsH scaffold or grafted S6 ATPase domain. The affinity of this grafted protein for gankyrin was first assessed using a pull-down assay in E. coli. Binding face residues on gankyrin or FtsH-S6 ATPase were mutated to alanine, on the basis of the findings of Yokoyama and co-workers, and their effect on complex stability was qualitatively assessed by measuring the amount of untagged FtsH-S6 ATPase co-purified with gankyrin-His 6x .
Most (Figure 2c , lane 5) appear to form complexes that are significantly less stable than the native proteins. This is in contrast to Yokoyama's original pull-down assay, in which all mutants but R342A S6 ATPase were not appreciably copurified with gankyrin-His 6x . This highlights a potential virtue of our grafting approach. It is unclear if mutations to this unstable form of S6 ATPase appreciably modulate, or abolish, gankyrin−S6 ATPase complex stability or simply further decrease the level of structure and stability of the C-terminal S6 ATPase fragment.
While the FtsH scaffold displays S6 ATPase in a manner that faithfully mimics the native protein (facilitates binding to gankyrin), no information about the exact differences in binding energies can be obtained using the pull-down assay. Moreover, mutational effects that do not dramatically lower, or completely abolish, complex stability cannot be probed using this assay. Only through the described grafting strategy are we able to create a soluble and stable mimic of S6 ATPase, which permits the use of more sensitive biophysical methods for probing this important binding interaction.
We used isothermal titration calorimetry (ITC) to obtain the full thermodynamic signature (ΔH, −TΔS, and ΔG) and stoichiometry (N value) of this interaction, as well as characterize mutational effects on complex stability. Gankyrin binds the grafted FtsH-S6 ATPase with a dissociation constant (K D ) of ∼67 nM (Table 1 , entry 1). The observed changes in enthalpy (ΔH) and entropy (−TΔS) for this binding interaction were −28.7 and 19.0 kcal/mol, respectively. Gankyrin does not bind wild-type FtsH with any appreciable affinity (Supporting Information, Figure S2 ), which is unsurprising, given that the S6 and FtsH ATPase subdomains share only ∼24% sequence homology.
Alanine mutation of S6 ATPase R342, which engages gankyrin through a salt bridge with gankyrin E182, modestly lowers complex stability [K D = 216.6 ± 25.8 nM (Table 1, entry 2)]. Double (R338A/R342A) and triple (R338A/R339A/ R342A) mutation of a positively charged patch on the S6 ATPase face, which disrupts a salt bridge between S6ATPase R342 and gankyrin E182, dramatically lowers complex stability [K D values of 2.5 ± 0.4 and 7.5 ± 0.2 μM (Table 1, entries 3 and 4, respectively)]. Interestingly, both of these mutations result in favorable binding entropies (−TΔS values of −1.5 ± 0.8 and −4.7 ± 0.1 kcal/mol, repectively, compared to a −TΔS of 19.0 ± 0.6 for the native interaction). While the molecular mechanism for this dramatic change is unclear, one possible rationale is a lower energy of desolvation for the alanine mutants, compared to that of the native protein. While Yokoyama's original pull-down data suggest a significant role for S6 ATPase E356/E357 in complex stability, double alanine Collectively, our findings represent the first quantitative assessment of the binding interaction, and binding thermodynamics, of a physiologically relevant complex involving the oncoprotein gankyrin. These data also potentially establish a target affinity for therapeutic reagents designed to inhibit gankyrin-dependent protein−protein interactions. 11, 12 ■ ASSOCIATED CONTENT * S Supporting Information Experimental details, polyacrylamide gel electrophoresis gel analysis, sequences of all proteins used in this work, and representative isothermal titration calorimetry binding isotherms for each entry in Table 1 . This material is available free of charge via the Internet at http://pubs.acs.org.
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